Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

International Stem Cell (ISCO) Asset Writedowns and Impairment (2016 - 2019)

Historic Asset Writedowns and Impairment for International Stem Cell (ISCO) over the last 9 years, with Q4 2019 value amounting to $1.4 million.

  • International Stem Cell's Asset Writedowns and Impairment rose 46707.32% to $1.4 million in Q4 2019 from the same period last year, while for Sep 2024 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $2000.0 for FY2024, which is N/A changed from last year.
  • International Stem Cell's Asset Writedowns and Impairment amounted to $1.4 million in Q4 2019, which was up 46707.32% from $246000.0 recorded in Q4 2018.
  • Over the past 5 years, International Stem Cell's Asset Writedowns and Impairment peaked at $1.4 million during Q4 2019, and registered a low of $2000.0 during Q2 2016.
  • Its 5-year average for Asset Writedowns and Impairment is $245533.3, with a median of $93000.0 in 2018.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first tumbled by 9574.47% in 2016, then soared by 380416.67% in 2017.
  • Over the past 5 years, International Stem Cell's Asset Writedowns and Impairment (Quarter) stood at $77000.0 in 2015, then crashed by 68.83% to $24000.0 in 2016, then soared by 3804.17% to $937000.0 in 2017, then plummeted by 73.75% to $246000.0 in 2018, then soared by 467.07% to $1.4 million in 2019.
  • Its Asset Writedowns and Impairment was $1.4 million in Q4 2019, compared to $246000.0 in Q4 2018 and $157000.0 in Q3 2018.